CBS 2019
CBSMD教育中心
中 文

肺动脉高压

Abstract

Recommended Article

Management of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension A Notch3-Marked Subpopulation of Vascular Smooth Muscle Cells Is the Cell of Origin for Occlusive Pulmonary Vascular Lesions. Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension Pulmonary hypertension is associated with an increased incidence of NAFLD: A retrospective cohort study of 18,910 patients The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Treatment Effects of Pulmonary Artery Denervation for Pulmonary Arterial Hypertension Stratified by REVEAL Risk Score: Results from PADN-CFDA Trial

Recommandation StatementVolume 12, Issue 9, May 2019

JOURNAL:JACC Cardiovasc Interv. Article Link

Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document

E Spitzer, E McFadden, PW Serruys et al. Keywords: bleeding; clinical endpoint; adjudication; clinical endpoint definition; death; myocardial infarction; revascularization; scaffold thrombosis; stent thrombosis; stroke

ABSTRACT


The Academic Research Consortium (ARC) and the Standardized Data Collection for Cardiovascular Trials Initiative have recently published updated clinical and angiographic endpoint definitions for percutaneous coronary intervention trials. The aim of this document is to provide practical guidance to facilitate and harmonize the implementation of those definitions in randomized trials or registries, as well as to foster consistency among independent adjudication committees. The authors compared the ARC-2 and Standardized Data Collection for Cardiovascular Trials Initiative definitions to identify areas of consistency, complex scenarios, and definitions in need of further standardization. Furthermore, the authors compared the fourth universal definition of myocardial infarction with the ARC-2 definition of myocardial infarction. The Society for Cardiovascular Angiography and Interventions definition of periprocedural myocardial infarction was also compared with the ARC-2 definition and the fourth universal definition of myocardial infarction. An in-depth assessment was done for each individual clinical endpoint to guide clinical investigators on reporting and classifying clinical adverse events. Finally, the authors propose standard streamlined data capture templates for reporting and adjudicating death, myocardial infarction, stroke, revascularization, stent or scaffold thrombosis, and bleeding.